# Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

> **NCT02628067** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1609 (estimated)

## Conditions studied

- Advanced Cancer
- Anal Carcinoma
- Anal Cancer
- Biliary Cancer
- Cholangiocarcinoma
- Bile Duct Cancer
- Neuroendocrine Tumor
- Carcinoid Tumor
- Endometrial Carcinoma
- Endometrial Cancer
- Cervical Carcinoma
- Cervical Cancer
- Vulvar Carcinoma
- Vulvar Cancer
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer (SCLC)
- Mesothelioma
- Thyroid Carcinoma
- Thyroid Cancer
- Salivary Gland Carcinoma
- Salivary Gland Cancer
- Salivary Cancer
- Parotid Gland Cancer
- Advanced Solid Tumors
- Colorectal Carcinoma

## Interventions

- **BIOLOGICAL:** pembrolizumab
- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT02628067
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-12-18
- **Primary completion:** 2027-05-04
- **Final completion:** 2027-05-04
- **Target enrollment:** 1609 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02628067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02628067, "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02628067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*